Shen, L., Bai, Y., Lin, X., Li, W., Wang, J., Zhang, X., Pan, H., Bai, C., Bai, L., Cheng, Y., Zhang, J., Zhong, H., Ba, Y., Hu, W., Xu, R., Guo, W., Qin, S., Hu, N., McCraith, S., Liu, T. (2025). First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up of Chinese pts from CheckMate 649.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.4_suppl.392